Basel Medical reported asset growth of 3.98% for the quarter ended Dec 2025. These growth metrics cover 3 quarters of results from Dec 2024 through Dec 2025, standardized by Business Quant from the company’s SEC filings.
| Growth Metrics | Dec2024 | Jun2025 | Dec2025 |
|---|---|---|---|
| Growth Ratios | |||
| Assets Growth (1y) | 19.05% | 3.98% | |
| Capital Expenditures Growth (1y)Capex Growth (1y) | -131.78% | ||
| Cash & Equivalents Growth (1y)Cash & Equiv. Growth (1y) | 62.19% | ||
| EBIT Growth (1y) | -88.11% | ||
| EBT Growth (1y) | -83.66% | ||
| EPS (Basic) Growth (1y) | 282.56% | ||
| EPS (Diluted) Growth (1y) | 282.56% | ||
| Free Cash Flow Growth (1y)FCF Growth (1y) | -43,973.24% | ||
| Interest Coverage Ratio Growth (1y)Interest Cover Growth (1y) | 88.29% | ||
| Net Cash Flow Growth (1y)NCF Growth (1y) | -736.27% | ||
| Net Income Growth (1y) | -87.57% | ||
| Net Income towards Common Stockholders Growth (1y)Net Income Growth (1y) | -112.91% | 311.05% | |
| Profit After Tax Growth (1y)PAT Growth (1y) | -76.10% | ||
| Property, Plant & Equipment (Net) Growth (1y)PP&E (Net) Growth (1y) | 4,047.41% | 862.49% | |
| Share-based Compensation Growth (1y)Stock Comp. Growth (1y) | -116.33% | -96.22% | |
| Tax Rate Growth (1y) | 3,143.00 | ||
| Total Debt Growth (1y) | 6.95% | -15.30% |